Visualizing the Future: Advances in IL-23-Targeted Therapies in the Treatment of IBD.
Interleukin (IL)-23 has been identified as a main driver of inflammation in the pathology of inflammatory bowel disease (IBD). While all agents in this anti-IL-23 class neutralize IL-23 by binding of the Fab fragment, differences in Fc fragment may be …